Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

This corresponded to 0.7 MIs and 1.2 strokes avoided per 100 patients up to 24 months. "Sotagliflozin is the first SGLT inhibitor to provide a significant reduction in both myocardial infarction ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...